The lecture duration is 18min.
0.5 CPD Points, 0.5 CEUs, 0.5 CME credits approval pending.
Accredited by CPDUK, CBRN and Provider Pending.
You can watch this lecture for free! For premium features, including a CPD/CME accredited certificate, to use time-coded note taking or get downloadable slides, you will need a fair price subscription.
To improve the outcome of Candida sepsis, early diagnosis and its distinction from bacterial sepsis is of paramount importance. Despite the improvement of diagnosis in recent years with the introduction of T2 magnetic resonance nano-particle-based and MALDI-TOF techniques, a considerable number of patients are usually treated empirically due to poor sensitivity and long turnaround time of conventional technique. Antifungal prophylaxis should be restricted to the cohorts of high-risk (>10%) of Candida sepsis. The patients with positive clinical predictive values and long-stay in intensive care units, acute necrotizing pancreatitis, and recurrent gastrointestinal perforations are some of those high-risk groups. While choosing antifungal for empiric or targeted therapy, preference should be given to fungicidal (echinocandins, polyenes) drugs. However, species identification and antifungal susceptibility testing would help to choose the right drug. The other issues including early central venous catheter removal, ophthalmic examination in second week, therapeutic drug monitoring require serious attention, though deprived of consensus regarding the need and optimal time for the procedure. Finally, the delivering antimicrobial stewardship agenda will not be possible without improvement of diagnosis of Candida sepsis.
Emergency Medicine Doctors
Emergency Medicine Nurses
Paramedics
Rural GP's
Upon completion of this activity, you should be able to:
None.